Filing Flows › Orchestra BioMed Holdings (OBIO) › Q1 2026 › vs Q1 2025
Orchestra BioMed Holdings (OBIO) Q1 2026 vs Q1 2025 (year over year)
Orchestra BioMed Holdings's revenue fell $758K (-87%) from $868K in Q1 2025 to $110K in Q1 2026.
Orchestra BioMed Holdings, Q1 2026: revenue $110K (-87% year over year), net loss $20.7M, operating cash flow −$22.2M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $110K | $868K | −$758K | -87% |
| Other income, net | $1.4M | $166K | $1.2M | +734% |
| Net loss | $20.7M | $18.8M | $1.9M | +10% |
| Costs & expenses | $22.2M | $19.8M | $2.4M | +12% |
| Operating costs | $22.2M | $19.8M | $2.4M | +12% |
| Cost of revenue | $32K | $44K | −$12K | -27% |
| Research & development | $15.8M | $13.5M | $2.3M | +17% |
| SG&A | $6.4M | $6.3M | $110K | +2% |
| Operating cash sources | $25.1M | $19.7M | $5.4M | +28% |
| Depreciation & amortization | $90K | $83K | $7K | +8% |
| Share-based compensation | $2.9M | $3.0M | −$114K | -4% |
| Cash used in operations | $22.2M | $16.6M | $5.6M | +33% |
| Net loss absorbed | $20.7M | $18.8M | $1.9M | +10% |
| Working capital & other | $4.4M | $909K | $3.5M | +386% |
Questions
How much did Orchestra BioMed Holdings's revenue grow year over year in Q1 2026?
Orchestra BioMed Holdings's revenue fell $758K (-87%) from $868K in Q1 2025 to $110K in Q1 2026.